Dear editor

Recent research article of “Prognostic implications of ischemia modified albumin in known cases of 86 elderly hypertensive South Asian aged 56-64 years: a hospital based study[1]” has resulted in a great deal of interest among us in addressing the following points. We deeply appreciate this pilot research on the value of ischemia modified albumin (IMA) among hypertensives and normotensives. A quick search of Medline produced two related but conflicting reports[2,3]. In one report, Sbarouni et al. found no difference in IMA level between hypertensives and normal controls[2]. Whereas, in other recent study, it was reported significantly higher level of IMA in hypertensive patients in comparison to controls[3]. Although this finding is in line with the reported research, it was surprisingly not cited in their paper[1].

This study involves the estimation of IMA by a previously described albumin cobalt binding assay measuring the colour developed by unbound cobalt using dithiothreitol. As it is well known that IMA value depend on albumin level. It is important to report both albumin value and IMA result corrected for albumin[4]. This appears to be of great importance in view of recent study reporting an association between the cardio protective serum albumin and blood pressure, a cardiovascular risk factor[5].

Furthermore, despite showing significant increase in the levels of cholesterol, triglycerides, low density lipoproteins and decreased high density lipoproteins in hypertension group, there is no information on free fatty acid (FFA) level that would have been addressed. It is well known knowledge that the FFAs and bilirubin in circulation are predominantly bound to serum albumin[6,7]. This could as a consequence able to interfere with albumin cobalt binding assay affecting IMA values[8].

Delving into the literature revealed important information that FFAs allosterically inhibit cobalt binding to albumin, diminish the overall cobalt binding to heterogeneous system architecture[8-10]. Interestingly, elevated FFAs have been reported as an independent risk factor for hypertension[11] and were
reported to modulate microvascular function[12]. FFAs impair endothelium dependent vasodilation[13], independent correlates of blood pressure[14] contributing to hypertension and increased cardiovascular risk. In addition to their elevation in hypertension, increased FFAs concentration also induces oxidative stress[15]. Interestingly, it was reported that the serum bilirubin level was significantly lower in the untreated hypertensives when compared with normotensives or the treated hypertensives[16]. Therefore, we speculate that this sounds like a necessary to study the level of FFAs, bilirubin and their effect in relation to IMA, an ischemic and oxidative stress marker as well.

Although the authors had been concluded that IMA could be incorporated as a diagnostic test parameter in hypertension patients[1], there is no information on the receiver operating curve analysis for IMA between hypertensive patients and normotensives controls. Such statements stand applicable or would be more meaningful with the data on diagnostic cutoff values for IMA in hypertensive subjects.

Despite the aforementioned information, it is of much importance that this study demonstrated valuable information on IMA levels in hypertension in comparison to normotensive controls. We hope the points highlighted by us in this commentary letter would be carried forward through further research. Future extension of this research on these aspects would be highly appreciated and may yield useful scientific information, possibly.

**Conflict of interest statement**

We declare that we have no conflict of interest.

**References**

[1] Kumar A. Prognostic implications of ischemia modified albumin in known cases of 86 elderly hypertensive South Asian aged 56–64 years – a hospital based study. *Asian Pac J Trop Dis* 2014; 4(Suppl 1): S429-34.

[2] Sbarouni E, Georgiadou P, Manginas A, Panagiotakos D, Karavolias GK, Voudris V. Ischaemia-modified albumin in pulmonary hypertension. *Biomarkers* 2010; 15(3): 238-42.

[3] Toker A, Mehmetoğlu I, Yerlikaya FH, Nergiz S, Kurban S, Gök H. Investigation of oxidative stress markers in essential hypertension. *Clin Lab* 2013; 59(1-2): 107-14.

[4] Ahn JH, Choi SC, Lee WG, JungYS. The usefulness of albumin-adjusted ischemia-modified albumin index as early detecting marker for ischemic stroke. *Neurol Sci* 2011; 32(1): 133-8.

[5] Høstmark AT, Tomten SE, Berg JE. Serum albumin and blood pressure: a population-based, cross-sectional study. *J Hypertens* 2005; 23(4): 725-30.

[6] Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. *J Emerg Med* 2000; 19(4): 311-5.

[7] Coomes MW. Amino acid metabolism. In: Devlin TM, editor. *Textbook of Biochemistry, with clinical correlations*. New York: Wiley-Liss; 2006. p. 743-87.

[8] Bhagavan NV, Ha JS, Park JH, Honda SA, Rios CN, Sugiyama C, et al. Utility of serum fatty acid concentrations as a marker for acute myocardial infarction and their potential role in the formation of ischemia-modified albumin: a pilot study. *Clin Chem* 2009; 55(8): 1588-90.

[9] Lu J, Stewart AJ, Sadler PJ, Pinheiro TJ, Blindauer CA. AllostERIC inhibition of cobalt binding to albumin by fatty acids: implications for the detection of myocardial ischemia. *J Med Chem* 2012; 55(9): 4425-30.

[10] Amirtharaj GJ, Natarajan SK, Mukhopadhya A, Zachariah UG, Hegde SK, Kurian G, et al. Fatty acids influence binding of cobalt to serum albumin in patients with fatty liver. *Biochim Biophys Acta-Mol Basis Dis* 2008; 1782(5): 349-54.

[11] Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetière P, et al. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. *Int J Epidemiol* 1998; 27(5): 808-13.

[12] de Jongh RT, Serné EH, Ijzerman RG, de Vries G, Stenhouwer CD. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. *Diabetes* 2004; 53(11): 2873-82.

[13] Steinberg HO, Tarshoby M, Nonestel R, Hook G, Cronin J, Johnson A, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. *J Clin Invest* 1997; 100(5): 1230-9.

[14] Simon JA, Fong J, Bernert JT Jr. Serum fatty acids and blood pressure. *Hypertension* 1996; 27(2): 303-7.

[15] Tripathy D, Mohanty P, Dhinda S, Syed T, Ghanim H, Aljada A, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. *Diabetes* 2003; 52(12): 2882-7.

[16] Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. *Am J Hypertens* 1999; 12(7): 673-81.